The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Vonvendi, Takeda’s recombinant von Willebrand factor (rVWF) therapy, marking a significant advancement in the management of rare bleeding disorders. According to The Pharma Letter, Vonvendi, originally approved for adults with von Willebrand disease (VWD), can now be used for routine prophylaxis to reduce the frequency of bleeding episodes in both adults and children aged six and older with severe Type 3 VWD who are at high risk of bleeding.
Von Willebrand disease is the most common inherited bleeding disorder, caused by a deficiency or dysfunction of von Willebrand factor, a critical protein involved in blood clotting. Type 3 VWD, the most severe form, leaves individuals vulnerable to frequent and sometimes life-threatening bleeding episodes, including joint bleeds and gastrointestinal hemorrhages. Previously, treatment options for routine prevention of bleeding in these patients were limited, often relying on plasma-derived therapies that can carry the risk of viral transmission and allergic reactions.
Vonvendi is the first and only recombinant von Willebrand factor concentrate approved in the U.S. This means it is produced using recombinant DNA technology rather than being derived from human plasma, offering a safer and more consistent product. The expanded FDA approval is backed by clinical trial data demonstrating Vonvendi’s effectiveness in preventing bleeding episodes when used as a regular prophylactic treatment, rather than solely for on-demand management of acute bleeds or during surgical procedures.
The pivotal phase 3 study supporting this decision showed that patients with severe Type 3 VWD who received routine prophylaxis with Vonvendi experienced significantly fewer bleeding episodes compared to their historical bleeding rates. The therapy was generally well tolerated, with a safety profile consistent with previous findings.
The new indication allows for greater flexibility and peace of mind for patients and healthcare providers. Children as young as six with severe Type 3 VWD can now benefit from a preventive therapy that reduces the burden of bleeding and improves quality of life. This is particularly important for pediatric patients, who are at risk for joint damage and other complications from repeated bleeds.
Takeda, the manufacturer of Vonvendi, has emphasized the importance of this expanded approval as a milestone for the bleeding disorders community. The company notes that the availability of a recombinant prophylactic option aligns with modern standards of care and reflects ongoing innovation in the treatment of rare hematological conditions.
